Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

Furthermore, existing biomarkers, such as CA19-9, are not reliable on their own to detect early-stage pancreatic cancer. Goel, Xu, and colleagues explored the potential of an exosome-based liquid ...

The biomarkers, identified using Liquid's EMERGE platform, demonstrated a 95% sensitivity and 98% specificity in detecting pancreatic cancer across multiple study cohorts. These promising results ...

"Unlike traditional imaging, which requires specific equipment and expertise, liquid biopsy could become a widely accessible ...

has entered into an exclusive licensing agreement with Liquid Biosciences to develop a blood test for the detection of pancreatic cancer. The test utilizes a portfolio of mRNA biomarkers and a ...

Opens in a new tab or window The blood test achieved high accuracy, with 98% specificity and 73% sensitivity for detecting pancreatic ... of proteins in liquid biopsy-based cancer detection ...

Liquid biopsies are poised to redefine cancer care by integrating the principles of care convergence and aligning diagnostics and treatment across disciplines. Care convergence isn’t just a ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ... Algorithm Based on Liquid Biosciences EMERGE Platform ...